Publication:
2022 American college of rheumatology/EULAR classification criteria for Takayasu arteritis

dc.contributor.authorDİRESKENELİ, RAFİ HANER
dc.contributor.authorsGrayson P. C., Ponte C., Robson J. C., Gribbons K. B., Judge A., Craven A., Khalid S., Hutchings A., Danda D., Luqmani R. A., et al.
dc.date.accessioned2023-11-20T08:29:18Z
dc.date.accessioned2026-01-10T20:28:22Z
dc.date.available2023-11-20T08:29:18Z
dc.date.issued2022-12-01
dc.description.abstractObjective: To develop and validate new classification criteria for Takayasu arteritis (TAK). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 6 phases: 1) identification of candidate criteria items, 2) collection of candidate items present at diagnosis, 3) expert panel review of cases, 4) data-driven reduction of candidate items, 5) derivation of a points-based classification score in a development data set, and 6) validation in an independent data set. Results: The development data set consisted of 316 cases of TAK and 323 comparators. The validation data set consisted of an additional 146 cases of TAK and 127 comparators. Age ≤60 years at diagnosis and imaging evidence of large-vessel vasculitis were absolute requirements to classify a patient as having TAK. The final criteria items and weights were as follows: female sex (+1), angina (+2), limb claudication (+2), arterial bruit (+2), reduced upper extremity pulse (+2), reduced pulse or tenderness of a carotid artery (+2), blood pressure difference between arms of ≥20 mm Hg (+1), number of affected arterial territories (+1 to +3), paired artery involvement (+1), and abdominal aorta plus renal or mesenteric involvement (+3). A patient could be classified as having TAK with a cumulative score of ≥5 points. When these criteria were tested in the validation data set, the model area under the curve was 0.97 (95% confidence interval [95% CI] 0.94–0.99) with a sensitivity of 93.8% (95% CI 88.6–97.1%) and specificity of 99.2% (95% CI 96.7–100.0%). Conclusion: The 2022 American College of Rheumatology/EULAR classification criteria for TAK are now validated for use in research.
dc.identifier.citationGrayson P. C., Ponte C., Robson J. C., Gribbons K. B., Judge A., Craven A., Khalid S., Hutchings A., Danda D., Luqmani R. A., et al., "2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis", Arthritis and Rheumatology, cilt.74, sa.12, ss.1872-1880, 2022
dc.identifier.doi10.1002/art.42324
dc.identifier.endpage1880
dc.identifier.issn2326-5191
dc.identifier.issue12
dc.identifier.startpage1872
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/626fa8d3-ccd4-4d6b-8b98-9df5b9cc2f89/file
dc.identifier.urihttps://hdl.handle.net/11424/294983
dc.identifier.volume74
dc.language.isoeng
dc.relation.ispartofArthritis and Rheumatology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectImmunology and Rheumatology
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectİmmünoloji
dc.subjectALERJİ
dc.subjectROMATOLOJİ
dc.subjectClinical Medicine (MED)
dc.subjectLife Sciences (LIFE)
dc.subjectCLINICAL MEDICINE
dc.subjectIMMUNOLOGY
dc.subjectALLERGY
dc.subjectRHEUMATOLOGY
dc.subjectİmmünoloji ve Alerji
dc.subjectRomatoloji
dc.subjectImmunology and Allergy
dc.subjectRheumatology
dc.subjectImmunology
dc.title2022 American college of rheumatology/EULAR classification criteria for Takayasu arteritis
dc.typearticle
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
889.76 KB
Format:
Adobe Portable Document Format